Please wait while the formulary information is being retrieved.
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE)
- Pregnancy contraception
- Endometrial carcinoma
- Renal cell carcinoma
150 mg/mL intramuscular suspension
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
400 mg/mL intramuscular suspension
- Inject 1 milliliter (400 mg) by intramuscular route once a month
medroxyprogesterone 150 mg/mL intramuscular suspension
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
medroxyprogesterone 400 mg/mL intramuscular suspension
- Inject 1 milliliter (400 mg) by intramuscular route once a month
150 mg/mL intramuscular suspension
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
400 mg/mL intramuscular suspension
- Inject 1 milliliter (400 mg) by intramuscular route once a month
Endometrial carcinoma
- Inject 2.5 milliliters (1,000 mg) by intramuscular route once weekly
- Inject 2.5 milliliters (1,000 mg) by intramuscular route once a month
- Inject 1 milliliter (400 mg) by intramuscular route once a month
- Inject 1 milliliter (400 mg) by intramuscular route once weekly
Endometriosis
- Inject 150 mg by intramuscular route every 3 months
- Inject 0.33 milliliter (50 mg) by intramuscular route once weekly forat least 6 months
- Inject 0.67 milliliter (100 mg) by intramuscular route every 2 weeks for at least 6 months
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months for at least 6 months
Pregnancy contraception
- Inject 150 mg by intramuscular route every 3 months
- Inject 1 milliliter (150 mg) by intramuscular route every 3 months
Renal cell carcinoma
- Inject 2.5 milliliters (1,000 mg) by intramuscular route once weekly
- Inject 2.5 milliliters (1,000 mg) by intramuscular route once a month
- Inject 1 milliliter (400 mg) by intramuscular route once a month
- Inject 1 milliliter (400 mg) by intramuscular route once weekly
- sodium tetradecyl sulfate
- Sotradecol
Contraindicated
- Aptivus
- artemether-lumefantrine
- atazanavir
- Atripla
- B cplx-C-St.Johnwrt-K.&S.ginsg
- Banzel
- boceprevir
- bosentan
- calcium-mag-B complex-D3-hrb61
- carbamazepine
- Carbatrol
- Cellcept
- Cellcept Intravenous
- chloramphenicol sod succinate
- clobazam
- Coartem
- Cold & Flu Fighter
- dabrafenib
- darunavir
- efavirenz
- efavirenz-emtricitabin-tenofov
- elvitegr-cobicist-emtric-tenof
- Epitol
- Equetro
- Fatigue Relief Complex
- fosamprenavir
- Grifulvin V
- Gris-peg (ultramicrosize)
- griseofulvin microsize
- griseofulvin ultramicrosize
- Incivek
- Invirase
- isoniazid-rifamp-pyrazinamide
- Kaletra
- Korlym
- Lexiva
- lopinavir-ritonavir
- mifepristone
- modafinil
- Mycobutin
- mycophenolate mofetil
- mycophenolate mofetil HCl
- mycophenolate sodium
- Myfortic
- nelfinavir
- nevirapine
- Norvir
- Norvir Soft Gelatin
- Onfi
- oxcarbazepine
- Oxtellar Xr
- Prezista
- Priftin
- Provigil
- Reyataz
- rifabutin
- Rifadin
- Rifamate
- rifampin
- rifampin-isoniazid
- rifapentine
- Rifater
- ritonavir
- rufinamide
- saquinavir mesylate
- St. John's wort
- Stribild
- Sustiva
- Tafinlar
- Tegretol
- Tegretol Xr
- telaprevir
- tipranavir
- Tracleer
- Trileptal
- Victrelis
- Viracept
- Viramune
- Viramune Xr
- vit C-St. John wort-elder-hb30
- Women's Complex
Severe
Moderate
- Adoxa
- aminophylline
- aprepitant
- Avidoxy
- demeclocycline
- Doryx
- Doxy-100
- doxycycline calcium
- doxycycline hyclate
- doxycycline monohydrate
- Dutoprol
- Elixophyllin
- Emend
- fosaprepitant
- Juxtapid
- lomitapide
- Lopressor
- Lopressor Hct
- metoprolol su-hydrochlorothiaz
- metoprolol succinate
- metoprolol ta-hydrochlorothiaz
- metoprolol tartrate
- Minocin
- minocycline
- Monodox
- Morgidox
- Oracea
- Solodyn
- tetracycline
- Theo-24
- Theochron
- theophylline
- theophylline in dextrose 5 %
- tigecycline
- Toprol Xl
- Tygacil
- Vibramycin
- Carcinoma of breast
- Cerebrovascular disorder
- Porphyria
- Predisposition to thrombosis
- Severe hepatic disease
- Thromboembolic disorder
- Thrombophlebitis
Contraindicated
- Osteopenia
- Osteoporosis
Severe
Moderate
- Breast fibroadenosis
- Depression
- Diabetes mellitus
- Edema
- Family history of malignant tumor of breast
- Hyperlipidemia
- Hypertension
- Weight gain
DEPO-PROVERA (MEDROXYPROGESTERONE ACETATE)
- Pregnancy contraception
- Endometrial carcinoma
- Renal cell carcinoma
- Abnormal vaginal bleeding
- Acute abdominal pain
- Dizziness
- General weakness
- Headache disorder
- Injection site sequelae
- Libido changes
- Menstrual disorder
- Nervousness
- Weight gain
More Frequent
Severe
Less Severe
- Depression
- Abdominal distension
- Acne vulgaris
- Alopecia
- Appetite changes
- Arthralgias
- Cramps in legs
- Dysmenorrhea
- Edema
- Fatigue
- Insomnia
- Mastalgia
- Nausea
- Skin rash
- Vaginal discharge
- Vaginitis
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
- Anemia
- Angioedema
- Carcinoma of cervix
- Deep venous thrombosis
- Disease of liver
- Endometrial hyperplasia
- Erythema multiforme
- Erythema nodosum
- Facial palsy
- Fracture
- Galactorrhea not associated with childbirth
- Hypercalcemia
- Hypercortisolism
- Neoplasm of breast
- Obstructive hyperbilirubinemia
- Osteopenia
- Osteoporosis
- Papilledema
- Pulmonary thromboembolism
- Rectal bleeding
- Retinal thrombosis
- Scleroderma
- Seizure disorder
- Thromboembolic disorder
- Thrombophlebitis
Less Severe
- Abnormal glucose tolerance
- Amenorrhea
- Body fluid retention
- Body odor
- Chloasma
- Drowsy
- Dry skin
- Erosion of cervix
- Euphoria
- Fever
- Flushing
- Hirsutism
- Hoarseness
- Increased libido
- Induration of skin
- Lactation deficiency
- Lipodystrophy
- Malaise
- Paresthesia
- Polydipsia
- Pruritus of skin
- Urticaria
Contraindicated
None
Severe Precaution
Medroxyprogesterone (Inj)
Not indicated before menarche. May affect bone development/density.
No safety and efficacy for use in endometrial or renal carcinoma. Reduces bone mineral density.
- 1 Day – 11 Years
- Not indicated before menarche. May affect bone development/density.
- No safety and efficacy for use in endometrial or renal carcinoma. Reduces bone mineral density.
- 11 Years – 18 Years
- Not indicated before menarche. May affect bone development/density.
- No safety and efficacy for use in endometrial or renal carcinoma. Reduces bone mineral density.
Management or Monitoring Precaution
None
Medroxyprogesterone
- Severity Level:
2
- Additional Notes: Available data suggest little or no known risk for developmental toxicity
Contraindicated
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
Medroxyprogesterone
Human data indicate no known adverse effect on nursing infant
| General | Excretion Potential | Effect on Infant | Notes |
| No known risks; does not adversely affect lactation | Excreted | No adverse effect | Human data indicate no known adverse effect on nursing infant |
Contraindicated
None
Precaution Exists
Medroxyprogesterone Ac
Neuro/Psych-The Women's Health Initiative Memory Study demonstrated an increased relative risk (2.05, 95% CI) of probable dementia in the elderly when used in combination with estrogens.
| Organ / System | HEP | REN | CARD | ENDO | NEURO / PSYCH | PULM |
| Increased Risk / Adverse Effects | N | N | N | Y | N | N |
BEERS: N HEDIS: N STOPP: N
No Known Risk
None
- None
| Endometrial carcinoma | |
| C54.1 | Malignant neoplasm of endometrium |
| Pregnancy contraception | |
| Z30 | Encounter for contraceptive management |
| Z30.01 | Encounter for initial prescription of contraceptives |
| Z30.011 | Encounter for initial prescription of contraceptive pills |
| Z30.013 | Encounter for initial prescription of injectable contraceptive |
| Z30.014 | Encounter for initial prescription of intrauterine contraceptive device |
| Z30.015 | Encounter for initial prescription of vaginal ring hormonal contraceptive |
| Z30.016 | Encounter for initial prescription of transdermal patch hormonal contraceptive device |
| Z30.017 | Encounter for initial prescription of implantable subdermal contraceptive |
| Z30.018 | Encounter for initial prescription of other contraceptives |
| Z30.019 | Encounter for initial prescription of contraceptives, unspecified |
| Z30.4 | Encounter for surveillance of contraceptives |
| Z30.40 | Encounter for surveillance of contraceptives, unspecified |
| Z30.41 | Encounter for surveillance of contraceptive pills |
| Z30.42 | Encounter for surveillance of injectable contraceptive |
| Z30.43 | Encounter for surveillance of intrauterine contraceptive device |
| Z30.430 | Encounter for insertion of intrauterine contraceptive device |
| Z30.431 | Encounter for routine checking of intrauterine contraceptive device |
| Z30.433 | Encounter for removal and reinsertion of intrauterine contraceptive device |
| Z30.44 | Encounter for surveillance of vaginal ring hormonal contraceptive device |
| Z30.45 | Encounter for surveillance of transdermal patch hormonal contraceptive device |
| Z30.46 | Encounter for surveillance of implantable subdermal contraceptive |
| Z30.49 | Encounter for surveillance of other contraceptives |
| Z30.8 | Encounter for other contraceptive management |
| Z30.9 | Encounter for contraceptive management, unspecified |
| Z79.3 | Long term (current) use of hormonal contraceptives |
| Z97.5 | Presence of (intrauterine) contraceptive device |
| Renal cell carcinoma | |
| C64 | Malignant neoplasm of kidney, except renal pelvis |
| C64.1 | Malignant neoplasm of right kidney, except renal pelvis |
| C64.2 | Malignant neoplasm of left kidney, except renal pelvis |
| C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
| 0-9 | A-Z |
|---|---|
| C54.1 | Malignant neoplasm of endometrium |
| C64 | Malignant neoplasm of kidney, except renal pelvis |
| C64.1 | Malignant neoplasm of right kidney, except renal pelvis |
| C64.2 | Malignant neoplasm of left kidney, except renal pelvis |
| C64.9 | Malignant neoplasm of unspecified kidney, except renal pelvis |
| Z30 | Encounter for contraceptive management |
| Z30.01 | Encounter for initial prescription of contraceptives |
| Z30.011 | Encounter for initial prescription of contraceptive pills |
| Z30.013 | Encounter for initial prescription of injectable contraceptive |
| Z30.014 | Encounter for initial prescription of intrauterine contraceptive device |
| Z30.015 | Encounter for initial prescription of vaginal ring hormonal contraceptive |
| Z30.016 | Encounter for initial prescription of transdermal patch hormonal contraceptive device |
| Z30.017 | Encounter for initial prescription of implantable subdermal contraceptive |
| Z30.018 | Encounter for initial prescription of other contraceptives |
| Z30.019 | Encounter for initial prescription of contraceptives, unspecified |
| Z30.4 | Encounter for surveillance of contraceptives |
| Z30.40 | Encounter for surveillance of contraceptives, unspecified |
| Z30.41 | Encounter for surveillance of contraceptive pills |
| Z30.42 | Encounter for surveillance of injectable contraceptive |
| Z30.43 | Encounter for surveillance of intrauterine contraceptive device |
| Z30.430 | Encounter for insertion of intrauterine contraceptive device |
| Z30.431 | Encounter for routine checking of intrauterine contraceptive device |
| Z30.433 | Encounter for removal and reinsertion of intrauterine contraceptive device |
| Z30.44 | Encounter for surveillance of vaginal ring hormonal contraceptive device |
| Z30.45 | Encounter for surveillance of transdermal patch hormonal contraceptive device |
| Z30.46 | Encounter for surveillance of implantable subdermal contraceptive |
| Z30.49 | Encounter for surveillance of other contraceptives |
| Z30.8 | Encounter for other contraceptive management |
| Z30.9 | Encounter for contraceptive management, unspecified |
| Z79.3 | Long term (current) use of hormonal contraceptives |
| Z97.5 | Presence of (intrauterine) contraceptive device |
Formulary Reference Tool